Lean offers manufacturers a host of efficiencies, but they don't all work for GMP. Here are some ideas for translating best practices for a highly-regulated industry.
- FDA RIFs Might Delay Your Review — Here Are Tips For Mitigating
- PDG-FDA Town Hall Notes — DSCSA Readiness Is At Hand
- ICH Revises Q1 Guideline, Advancing Stability Testing Standards
- Common Manufacturing Challenges For LBP Formulations
- What CDMOs Wish Biotechs Knew Before Submitting An RFP
- 8 Actions To Redefine Sponsor–CDMO Relationships
- We Must Rethink The Solvents We Use For Peptide Synthesis
EDITOR'S DESK
-
From BPI West: An Upstream Scientist's Advice On Target Glycosylation
Bioprocess Online spoke to an upstream scientist at Bristol Myers Squibb during this year's BPI West. Here's what he had to say.
Bioprocess Online and Cell & Gene spoke with Takeda’s Amy Shaw at BPI West to discuss the industry and her key takeaways from the conference.
Bioprocess Online asked Nathan Lewis, Ph.D., to briefly explain the research he presented at BPI West 2025.
Editor Tyler Menichiello reviews the most compelling topics and sessions from this year's BioProcess International U.S. West.
Experts from Eli Lilly, NervGen, and Piramal Pharma Solutions discuss the myriad of ways peptide manufacturing can be improved, drawing on years of industry experience and insight.
GUEST COLUMNISTS
-
PDG-FDA Town Hall Notes — DSCSA Readiness Is At Hand
Data quality and exceptions handling were key discussion points during a March PDG-FDA town hall, where stakeholders shared updates on progress and unfinished work.
-
ICH Revises Q1 Guideline, Advancing Stability Testing Standards
In April 2025, the International Council for Harmonisation (ICH) released draft ICH Q1: Stability Testing of Drug Substances and Drug Products for public consultation. This new draft guideline represents the first major overhaul of global stability testing standards in over two decades.
-
Common Manufacturing Challenges For LBP Formulations
As more companies explore live biotherapeutic products, ensuring stability is likely to be front and center with unique challenges for oral and topical applications.
-
What CDMOs Wish Biotechs Knew Before Submitting An RFP
This author has worked with CDMOs across different programs and therapeutic modalities. Each experience reinforced the same lesson: a strong RFP can make or break a partnership.
-
8 Actions To Redefine Sponsor–CDMO Relationships
When viewing a CDMO as merely a service provider, interactions are often limited to completing tasks. This mindset can stifle innovation and problem-solving.
-
We Must Rethink The Solvents We Use For Peptide Synthesis
While the effectiveness of GLP-1 in weight loss is good news, the use of organic solvents in the GLP-1 synthesis and purification process is a growing pain that needs to be addressed.
-
Navigating Tariffs: Implications And Strategies For Pharmaceuticals Manufacturers
The U.S. tariffs on trading partners bring a whole new set of challenges, but there are tactics and strategies companies can deploy to help offset the cost and operational impacts.
-
Why You Need A Raw Material Control Strategy
You should start with the end goal in mind, but the first draft is almost never the last. These living documents should evolve as your team gains process knowledge.
BIOPROCESSING WHITE PAPERS
-
The Impact Of Annex 1 (2022) On Sterility Assurance
Airflow visualization studies, crucial for GMP compliance, validate unidirectional airflow effectiveness in contamination control. Discover their enhanced role in quality by design and revised Annex 1 guidelines.
-
Scaling Up Viral Vector Harvest With Ease And Regulatory Compliance4/11/2025
Explore how scalable, high-performance solutions can help you overcome the challenges of large-volume viral vector production and accelerate the delivery of life-changing gene therapies.
-
Oligonucleotides: Where We Are And Where We Would Like To Go9/8/2024
This presentation provides an overview of oligonucleotide bioanalysis's current status and future directions. We will look into the advantages and disadvantages of various bioanalytical techniques.
-
Revolutionizing Drug Discovery From "Undruggables" To AI6/10/2024
Explore four current trends in drug discovery, how each trend addresses some of the most crucial challenges in drug discovery, and the obstacles to their widespread adoption.
-
Cell Culture Process Scale-Up Challenges For Commercial-Scale PSC Manufacturing3/5/2025
Allogeneic cell therapies offer incredible promise, but scaling up PSC manufacturing presents unique challenges. Explore these hurdles along with solutions for consistent, high-quality production.
-
Process Development For Lyophilized Products10/16/2024
Learn to identify potential product failure points and design robust formulations and processes for lyophilized products backed by solid data.
BIOPROCESSING APP NOTES & CASE STUDIES
BIOPROCESS ONLINE CONTENT COLLECTIONS

This collection of articles digs into the industry’s growing focus on knowledge management as an indispensable facet of biomanufacturing and pharmaceutical development, exploring how it plays into risk management, quality, vendor relationships, and supply chain resilience.
More Content CollectionsFEATURED PRODUCTS AND SERVICES
ON-DEMAND WEBINARS
- Closed System And Custom Solutions For Bioproduction
- A Modern Environmental Monitoring System That Grows With Its Tasks
- Why And Where To Monitor In Aseptic Processing Areas
- Inside The Development Of An AAV8 Production Platform
- Sustainable Manufacturing Through Efficient BioProduction Unit Operations
INDUSTRY NEWS
NEWSLETTER ARCHIVE
- 04.30.25 -- Advance Your mAb Program's Success
- 04.30.25 -- Do Patient Needs Define Biologic Product Specifications?
- 04.29.25 -- Trends In U.S. Biomanufacturing: From Cell Line Development To Commercial Scale
- 04.29.25 -- Navigating Tariffs: Implications And Strategies For Pharmaceuticals Manufacturers
- 04.28.25 -- Ramping Up GMP-Compliant CAR-NK Manufacturing At Scale With iPSCs